A blood sample can be used to assess the severity and prognosis of frontotemporal lobar degeneration in the future
Biomarkers to support the diagnosis of frontotemporal lobar degeneration (FTLD) and to assess the severity and expected prognosis of the disease are needed. Neurofilament light chain (NfL) measured from a blood sample strongly correlates with the duration of the disease in FTLD patients and the rate of brain atrophy, according to a new study published by the University of Eastern Finland in the Annals of Clinical and Translational Neurology. FTLD is the second most common cause of degenerative and progressive dementing diseases in the working-age population after Alzheimer's disease.